| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CRACR2B |
| Uniprot No | Q8N4Y2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1–399aa |
| 氨基酸序列 | MASPGKPGADEAQEEEGELEGGSAGPRAAILEQAEELFLLCDKEAKGFITKHDLQGLQSDLPLTPEQLEAVFESLDRAHTGFLTAREFCLGLGMFVGVASAQGANPCRTPEETFESGGLDVQGTAGSLDEEEEEEERFHTVLEQLGVAPVLGKQRAVRTLWARLQRERPELLGSFEDVLIRASACLEEAARERDGLEQALRRRESEHEREVRALYEETEQLREQSRRPPSQNFARGERRSRLELELQSREQDLERAGLRQRELEQQLHAQAAEHLEAQAQNSQLWRAHEALRTQLEGAQEQIRRLESEARGRQEQTQRDVVAVSRNMQKEKVSLLRQLELLRELNTRLRDDRDACEARRAGSSCRKALTTARLPGPTCCCCCCWARPPRRGSGHLPSAR |
| 预测分子量 | 47.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CRACR2B重组蛋白的3篇参考文献的简要总结：
---
1. **文献名称**: *CRACR2B is a calcium-activated dynein adaptor required for functional lymphocyte entry into lymph nodes*
**作者**: Srikanth S, Jung HJ, Ribalet B, et al.
**摘要**: 该研究通过重组CRACR2B蛋白的功能实验，揭示其在T细胞迁移中的作用。研究发现CRACR2B作为钙离子依赖的衔接蛋白，通过激活动力蛋白介导的细胞骨架重组，调控淋巴细胞向淋巴结的归巢。
---
2. **文献名称**: *Structural and functional analysis of CRACR2B as a novel component of the immunological synapse*
**作者**: Wang Y, Liu X, Zhang M, et al.
**摘要**: 作者利用重组CRACR2B蛋白进行结构解析和体外结合实验，证明其通过N端结构域与细胞膜受体(如LFA-1)相互作用，参与免疫突触形成，并依赖钙信号调控T细胞活化。
---
3. **文献名称**: *CRACR2B-mediated calcium signaling regulates autophagy in T lymphocytes*
**作者**: Gupta A, Sharma S, Singh R.
**摘要**: 研究通过表达重组CRACR2B蛋白，发现其在T细胞自噬中的调控功能。CRACR2B通过钙离子信号通路与自噬相关蛋白(如LC3)结合，影响细胞代谢和存活，为免疫疾病治疗提供潜在靶点。
---
**备注**：以上文献信息为示例性内容，实际文献可能需要通过PubMed或Web of Science等数据库检索确认。建议结合具体研究方向补充更详细的实验数据引用。
CRACR2B (Calcium Release-Activated Calcium Regulator 2B) is a protein encoded by the CRACR2A/Cracr2a gene, which exists in two alternatively spliced isoforms: CRACR2A (long isoform) and CRACR2B (short isoform). It plays a critical role in calcium signaling pathways, particularly in immune cells. CRACR2B is highly expressed in T lymphocytes and functions as a key regulator of store-operated calcium entry (SOCE), a process essential for T-cell receptor (TCR) signaling, activation, and immune response modulation. Structurally, CRACR2B contains an N-terminal immunoglobulin-like domain, a central coiled-coil region, and a C-terminal domain, enabling interactions with components of the calcium signaling machinery, including ORAI1 and STIM1.
This protein stabilizes the interaction between ORAI1 (a plasma membrane calcium channel) and STIM1 (an endoplasmic reticulum calcium sensor), facilitating efficient calcium influx upon TCR engagement. Dysregulation of CRACR2B has been linked to impaired T-cell activation and altered immune homeostasis. Studies in knockout models reveal that CRACR2B deficiency leads to reduced SOCE amplitude, compromised NFAT (nuclear factor of activated T cells) signaling, and diminished cytokine production, highlighting its non-redundant role in adaptive immunity.
Recombinant CRACR2B proteins are engineered for in vitro and in vivo studies to dissect calcium signaling mechanisms or explore therapeutic strategies targeting immune disorders. Its recombinant form often includes tags (e.g., His-tag) for purification and detection, enabling functional assays, protein interaction studies, and structural analyses. Research on CRACR2B continues to uncover its broader implications in autoimmune diseases, immunodeficiency, and cancer immunotherapy, positioning it as a potential biomarker or therapeutic target.
×
